Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Gut

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis

It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 1.52 [0.92, 2.5]
1 study · 113 participants
Very low

Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis

It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 0.9 [0.7, 1.16]
1 study · 113 participants
Very low

Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found